Scarica l'app Stockscreener
2.92
4.29%
0.12
Dopo l'orario di chiusura:
2.92
Precedente Chiudi:
$2.80
Aprire:
$2.76
Volume 24 ore:
164.34K
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.37M
Reddito:
-
Utile/perdita netta:
$-4.21M
Rapporto P/E:
-53.28
EPS:
-0.0548
Flusso di cassa netto:
-
1 W Prestazione:
+16.33%
1M Prestazione:
-9.60%
6M Prestazione:
-97.27%
1 anno Prestazione:
-99.70%
Intervallo 1D:
$2.6673
$2.93
Intervallo di 1 settimana:
$2.55
$3.05
Portata 52W:
$2.21
$1,194.15
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Nome
Conduit Pharmaceuticals Inc
Settore
Industria
Telefono
(646) 491 9132
Indirizzo
4851 TAMIAMI TRAIL NORTH, NAPLES
Confronta CDT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
2.92 | 2.37M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Conduit Pharmaceuticals Inc Borsa (CDT) Ultime notizie
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Price Down 0.4% – What’s Next? - Defense World
Conduit Pharmaceuticals Enters Development Agreement With Manoira To Test Drugs In Animals: Retail Sees Stock Above $10 - MENAFN.com
Conduit Pharmaceuticals Enters Development Agreement With Manoira To Test Drugs In Animals: Retail Sees Stock Above $10 By Stocktwits - Investing.com India
Conduit Pharmaceuticals enters joint development agreement with Manoira - TipRanks
Conduit Pharma Expands Drug Pipeline to $15B Animal Health Market Through Zero-Cost Development Deal - Stock Titan
Conduit Pharmaceuticals Sets 2025 Annual Meeting Date - TipRanks
CDT stock plunges to 52-week low, hitting $3.21 amid steep decline By Investing.com - Investing.com South Africa
CDT stock plunges to 52-week low, hitting $3.21 amid steep decline - Investing.com India
Conduit Pharmaceuticals regains Nasdaq compliance - MSN
Conduit Pharmaceuticals receives approval for Nasdaq listing - MSN
Conduit Pharmaceuticals approved to transfer listing to Nasdaq Capital Market - TipRanks
Conduit Pharmaceuticals moves to Nasdaq Capital Market By Investing.com - Investing.com India
Conduit Pharma Gains Nasdaq Capital Market Approval, Transfer Effective May 23 - Nasdaq
Conduit Pharmaceuticals moves to Nasdaq Capital Market - Investing.com Australia
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market - The Manila Times
Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan
Conduit Pharmaceuticals meets Nasdaq listing standards By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals meets Nasdaq listing standards - Investing.com Australia
Conduit Pharmaceuticals Regains Compliance With Nasdaq's Bid Price, Equity Requirements - marketscreener.com
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance - The Manila Times
Conduit Pharmaceuticals Inc. Regains Compliance with Nasdaq Listing Requirements - Nasdaq
Upcoming Stock Splits This Week (May 19 to May 23) – Stay Invested - The Globe and Mail
Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic - MSN
Conduit Pharmaceuticals approves reverse stock split By Investing.com - Investing.com South Africa
Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic By Stocktwits - Investing.com India
Conduit Pharmaceuticals Announces Reverse Stock Split - TipRanks
Barclays PLC Buys 54,523 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) - Defense World
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - The Manila Times
Conduit Pharmaceuticals approves reverse stock split - Investing.com
Conduit Pharmaceuticals Inc. Announces 1-for-15 Reverse Stock Split Approval - Nasdaq
CONDUIT PHARMACEUTICALS INC. SEC 10-Q Report - TradingView
Conduit Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - The Manila Times
Conduit Pharmaceuticals Secures Korean Patent for AZD1656, Advancing Global Development Strategy for Autoimmune Disorders - Nasdaq
Conduit Pharmaceuticals Files New Patent For AZD5904 - marketscreener.com
In 2025, Will Conduit Pharmaceuticals Inc (NASDAQ: CDT) Be Bullish Or Bearish? - Stocksregister
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset - The Manila Times
Conduit Pharmaceuticals Approves Reverse Stock Split Amendments - TipRanks
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Shares Acquired by Geode Capital Management LLC - Defense World
Conduit Pharmaceuticals Inc Azioni (CDT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Conduit Pharmaceuticals Inc Azioni (CDT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nirland Ltd | 10% Owner |
Oct 04 '24 |
Sale |
0.10 |
1,368,991 |
140,458 |
7,031,009 |
| Nirland Ltd | 10% Owner |
Oct 07 '24 |
Sale |
0.10 |
939,009 |
96,530 |
6,092,000 |
| Nirland Ltd | 10% Owner |
Oct 01 '24 |
Sale |
0.11 |
1,250,000 |
141,375 |
10,233,177 |
| Nirland Ltd | 10% Owner |
Sep 30 '24 |
Sale |
0.12 |
1,016,823 |
122,019 |
11,483,177 |
| Nirland Ltd | 10% Owner |
Oct 02 '24 |
Sale |
0.10 |
333,177 |
34,251 |
9,900,000 |
| Regan Andrew | Director |
Jul 16 '24 |
Sale |
0.32 |
10,244,392 |
3,246,448 |
1,691,727 |
| Regan Andrew | Director |
Jul 17 '24 |
Sale |
0.26 |
1,514,100 |
391,092 |
177,627 |
| Regan Andrew | Director |
Jul 12 '24 |
Sale |
0.25 |
1,389,820 |
343,425 |
12,941,319 |
| Regan Andrew | Director |
Jul 11 '24 |
Sale |
0.29 |
882,952 |
260,253 |
14,331,139 |
| Regan Andrew | Director |
Jul 15 '24 |
Sale |
0.25 |
1,005,200 |
248,385 |
11,936,119 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):